Related Experiment Video
Updated: Feb 1, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following
Tingting Zhang1, Fubin Feng2, Wenge Zhao3
1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
Background:
We performed a network meta-analysis of randomized controlled trials (RCTs) to indirectly compare the efficacy of different targeted agents with fulvestrant for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor type 2-negative (HER2-) advanced breast cancer (ABC) following progression on prior endocrine therapy.
Methods:
The titles/abstracts were searched from the PubMed, EMBASE, and the Cochrane Library databases for RCTs to evaluate the efficacy of palbociclib plus fulvestrant vs alternative targeted therapies plus fulvestrant for postmenopausal HR+/HER2- ABC following progression on prior endocrine therapy. In addition, the primary measured outcome was progression-free survival (PFS) and objective response rate. The surface under the cumulative ranking (SUCRA) value of each treatment was calculated to achieve the best ranking for each treatment.
Results:
A total of 11 studies, including 4,178 patients in the network meta-analysis, were included and analyzed. In terms of the pooled hazard ratios (HRs) for PFS, palbociclib plus fulvestrant was superior to other target agents plus fulvestrant (HR=0.62, 95% credible interval [CrI]: 0.40-0.96; HR=0.62, 95% CrI: 0.47-0.96; for pictilisib plus fulvestrant and buparlisib plus fulvestrant, respectively). Ribociclib plus fulvestrant has no difference in abemaciclib plus fulvestrant and palbociclib plus fulvestrant (HR =1.02, 95% CrI =0.72-1.45; HR =1.22, 95% CrI =0.84-1.78). In terms of objective response rate, compared with placebo plus fulvestrant, abemaciclib plus fulvestrant, dovitinib plus fulvestrant, buparlisib plus fulvestrant, and palbociclib plus fulvestrant had a significant difference (odds ratio [OR] =2.84, 95% CrI =1.91- 4.31; OR =3.62, 95% CrI =1.21-12.48; OR =1.80, 95% CrI =1.25-2.60; and OR =2.52, 95% CrI =1.43- 4.72, respectively).
Conclusion:
According to the present study, palbociclib plus fulvestrant may be the optimal treatment for HR+/HER2- postmenopausal women with ABC after disease progression following endocrine therapy.
Insights
Palbociclib plus fulvestrant shows superior progression-free survival compared to other targeted agents for advanced hormone-receptor-positive breast cancer. This combination may be the optimal choice for postmenopausal women after endocrine therapy progression.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Advanced breast cancer (ABC) treatment requires effective therapies post-endocrine resistance.
- Hormone-receptor-positive (HR+) and human epidermal growth factor receptor type 2-negative (HER2-) subtypes represent a significant patient population.
- Identifying optimal targeted agents combined with fulvestrant is crucial for improving patient outcomes.
Purpose of the Study:
- To conduct a network meta-analysis comparing targeted agents plus fulvestrant against fulvestrant alone.
- To evaluate the efficacy of palbociclib plus fulvestrant versus alternative targeted therapies in HR+/HER2- ABC.
- To determine the optimal treatment strategy for patients progressing on prior endocrine therapy.
Main Methods:
- Network meta-analysis of randomized controlled trials (RCTs) sourced from PubMed, EMBASE, and Cochrane Library.
- Primary efficacy endpoints included progression-free survival (PFS) and objective response rate (ORR).
- Surface Under the Cumulative Ranking (SUCRA) analysis was used to rank treatment effectiveness.
Main Results:
- Palbociclib plus fulvestrant demonstrated superior PFS compared to pictilisib and buparlisib plus fulvestrant (HR=0.62).
- Ribociclib plus fulvestrant showed no significant difference compared to abemaciclib or palbociclib plus fulvestrant.
- Abemaciclib, dovitinib, buparlisib, and palbociclib plus fulvestrant significantly improved ORR compared to placebo plus fulvestrant.
Conclusions:
- Palbociclib plus fulvestrant emerges as a potentially optimal treatment for HR+/HER2- advanced breast cancer patients.
- This combination offers a promising therapeutic option for postmenopausal women experiencing disease progression after endocrine therapy.
- Further research may validate these findings and guide personalized treatment approaches.
More Related Videos
07:17A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Gene Therapy
Group Therapy
Endocrine Signaling
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...